Subscribe
19 April 2013Big Pharma

OFT accuses GSK of market abuse over pay-for-delay deals

The UK Office of Fair Trading (OFT) has accused pharmaceutical firm GlaxoSmithKline (GSK) of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.

More on this story

Big Pharma
GSK’s Seroxat pay-for-delay deals may restrict competition: AG
23 January 2020   GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility